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Abstract Following the publication of our paper regarding
a population-based model of doxorubicin pharmacokinetics
in children in Clinical Pharmacokinetics last year (Voller
et al. 54:1139–1149, 2015), we have received many
inquiries on the practical clinical consequences of this
model; however, a population-based model is only one of
the aspects to be taken into account when developing
dosing algorithms. In addition, any new method of dose
calculation would need clinical validation and, subse-
quently, a new clinical trial. However, such a trial, espe-
cially with regard to burden to the children involved,
requires optimal preparation and the selection of the best
hypotheses. The European Paediatric Oncology Off-Patent
Medicines Consortium (EPOC), represented by the authors,
would therefore like to initiate an interdisciplinary dis-
cussion on the clinical and pharmacological goals for dose
calculation. This current opinion summarizes the existing
knowledge on the pharmacokinetics and pharmacodynam-
ics of doxorubicin. Our aim was to define the clinical needs
as precisely as possible, with the intention of stimulating
discussion between the clinical pediatric oncologist and the
pediatric pharmacologist. By doing so, we hope to define
surrogates for best practice of a common doxorubicin dose
in children. The intent is for a trial to validate a rational
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Key Points
New data on the pharmacokinetics of doxorubicin in
children (0–18 years) have become available.
Current dosing algorithms show a high variability.
A well-defined target pharmacokinetic or
pharmacodynamic parameter for doxorubicin is
lacking.
Consensus between different treatment groups is
desirable to develop and validate safe and efficacious
dosing guidelines.
1 Introduction
The European Medicines Agency included doxorubicin on the
‘priority list’ (doc. ref. EMEA/197972/2007, London, June
2007) for medications with a high priority for further research
on pediatric use, with the absence of pharmacokinetic
knowledge being the most critical point. Based on this docu-
ment, the European Paediatric Oncology Off-Patent Medici-
nes Consortium (EPOC) set up a trial to investigate the
pharmacokinetics of doxorubicin in children. The pharma-
cokinetic phase-II-trial (EudraCT number 2009-011454-17,
short title: EPOC) was funded under the European Commis-
sion’s Seventh Framework Program, grant agreement number
222910. These regulatory and political activities had the
objective of including more detailed dosing information in the
summary of product characteristics and the package leaflets.
Doxorubicin is currently authorized for a number of
malignancies in children, such as acute lymphoblastic
leukemia (ALL), acute myeloid leukemia, Wilms’ tumor,
Ewing’s sarcoma, osteosarcoma, and soft tissue sarcoma.
Anthracyclines, such as doxorubicin, are currently used in
nearly 60 % of children diagnosed with cancer [2], with a
high impact on therapeutic success. Anthracyclines sig-
nificantly increase event-free survival in patients with
Ewing’s sarcoma, and are considered fundamental in the
treatment of lymphomas and many solid tumors (i.e. soft
tissue sarcomas, high-risk hepatoblastoma, and high-risk
renal tumors) [2, 3]. There is also a non-significant ten-
dency towards greater antitumor efficacy of anthracyclines
in children diagnosed with ALL [2].
However, the most threatening drawback of this drug
class is its dose-dependent late cardiotoxicity. Long-term
survivors of childhood cancer have approximately five- to
sixfold greater risk of cardiac dysfunction compared with
their healthy siblings [4]. When observing the same cohort
beyond the age of 35 years, the risk is increased by seven-
to eightfold [5], which highlights the progressively
increasing risk of cardiotoxicity with time.
The incidence of cardiotoxicity is clearly associated with
cumulative dose, with doses greater than 300 mg/m2
resulting in a higher risk of cardiotoxicity [6]. Nevertheless,
subclinical cardiotoxicity is already present at lower doses
[7]. Generally, cumulative dose as a surrogate for ‘applied
drug exposure’1 is an accepted biomarker for cardiac dam-
age. Because younger age at diagnosis, particularly below
4 years, has been associated with an inferior cardiac outcome
[8], dose reduction in the very young is mandated in virtually
all treatment protocols, following a long-established general
principle in pediatric oncology [9]. Nonetheless, the influ-
ence of doxorubicin pharmacokinetics on both antitumor
effect and cardiotoxicity remains unclear. The impact of a
reduced dose on in vivo dose intensity in children is therefore
largely unknown. Furthermore, high variability in the inci-
dence of cardiotoxicity, even after accounting for clinical
risk factors, might suggest an underlying genetic mecha-
nism. Several candidate genes have been identified but, to
date, no genes have impacted dosing guidelines [10].
In the past, it has been unclear whether drug elimination,
quantified as clearance (CL), is lower in the very young than
in older children. While one study indicated that CL is lower
[11], others did not observe this tendency [12–14]. Data of
our recent trial of doxorubicin in 101 children clearly prove
that CL (L/h/m2), corrected for body surface area (BSA), is
considerably lower in younger children [1]. Based on this
new information, we ask the question as to how a rational
dosing of doxorubicin in children can be achieved.
In order to stimulate this discussion, we visualize the
effects of common dose adaptations on hypothetical children
and real-life patients who participated in the trial [1]. Using
the data of the population pharmacokinetic model developed
for the EPOC trial, we consider how dosing guidelines based
on pharmacokinetic data could be designed in children.
2 Current Dosing Concepts in Children
In 1958, Pinkel et al. postulated, using methotrexate as an
example, that BSA should be the factor by which dosage in
anticancer treatment should be adapted [15]. Based on the
aim of reducing interindividual variability, BSA-based dos-
ing became the standard approach in pediatric oncology [9].
However, in some cases, dosing in infants is performed
based on body weight instead of BSA (with 30 kg e 1 m2).
1 For the purpose of this article, we are using the broad term drug
‘exposure’ to refer to dose (drug input into the body—along the lines
of the FDA Guideline ‘‘Exposure-Response Relationships—Study
Design, Data Analysis, and Regulatory Applications’’, 2003) and dose
‘intensity’ to refer to the plasma concentrations experienced by an
individual (quantified as AUC or average concentration).
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The ratio of BSA to body weight in neonates and very young
children far exceeds that of older children and adults due to
physiological and anatomical development [16]. Thus,
body-weight-based dosing in the youngest age group results
in lower doses and thereby lower exposure.
Data in adults suggest that obese patients might have a
more than twofold increase in exposure to doxorubicin
when administered based on BSA [17]. Thus, even though
no data in children are available, dosing based on BSA
might not be suitable for the constantly increasing sub-
group of morbidly obese patients.
An overview of commonly applied dose modifications,
based on BSA, body weight or a combination thereof, is
shown in Table 1. In case of BSA-based dosing, there is
inconsistency in the extent of dose reduction, e.g. a 33 %
reduction of the BSA-adjusted dose in children younger
than 7 months in one protocol, and a 50 % reduction in the
same population in another protocol.
In the case of weight-based dose adaptation, the weight
cut-off is highly variable. One protocol reduces the dose in
children up to 1 year of age or less than 12 kg, while others
recommend an additional reduction of the body-weight-
based dose by one-third in children younger than 7 months
or weighing less than 5 kg.
This brief overview highlights the variability and arbi-
trary nature of dose adaptations, directly leading to an
impact on drug exposure and dose intensity.
3 Evaluation of the Status Quo
3.1 Impact of Different Dose Recommendations
on Hypothetical Children from Different
Percentiles of Height and Body Weight
In order to study the impact of age and body weight on
different dosing algorithms, three children with different
body compositions were simulated. One child was assumed
to be in the 5th percentile, one child in the 50th percentile,
and one child in the 95th percentile of height and body
weight from birth to adulthood [18]. The influence of the
dose adaptations, presented in Table 1, on these three
patients was evaluated.
For comparison, a ratio was calculated based on the pro-
tocol-based dose divided by a reference dose. The reference
dose was defined as a dose adjusted only to the actual BSA of
the patient, while the protocol-based dose was as specified in
the various protocols presented in Table 1 (Eq. 1).
% of BSA dose
¼ Recommendeddoseaccording toprotocol mg½ 
Doseperm2 mg
m2
   individualBSAof thepatient m2½   100
ð1Þ
Inconsistencies in current protocols led to a difference in
the percentage of BSA dose of up to one-third (Fig. 1).
Table 1 Selection of dose reduction schemes for doxorubicin in children
Protocol Description Dose recommendation
BSA-based adaptations
A ALL-BFM \7 months: 67 % of BSA dose
C7 to\12 months: 75 % of BSA dose
C12 months: 100 % of BSA dose
B SIOP WT 2001 \7 months: 50 % of BSA dose
C7 months ? body weight\12 kg: 67 % of BSA dose
C7 months ? body weight C12 kg: 100 % of BSA dose
Body-weight-based adaptations
C CWS-2002, CWSSoTiSaR \7 months: 67 % of body-weight-based dose
C7 months to\12 months: 100 % of body-weight-based dose
C12 months: 100 % of BSA dose
D NB 2004/STS 2006 \12 months: 100 % of body-weight-based dose
C12 months ? body weight\10 kg: 100 % of body-weight-based dose
C12 months ? body weight C10 kg: 100 % of BSA dose
E SIOPEN HR-NBL-1 Body weight\5 kg: 67 % of body-weight-based dose
Body weight\12 kg: 100 % of body-weight-based dose
Body weight C12 kg: 100 % of BSA dose
BFM International BFM (Berlin, Frankfurt, Muenster) study group, BSA body surface area, CWS German cooperative soft tissue sarcoma group
(Cooperative Weichteilsarkom Studiengruppen), HR-NBL high risk neuroblastoma, NB neuroblastoma, SIOP International Society of Paediatric
Oncology, SIOPEN International Society of Pediatric Oncology Europe Neuroblastoma, SoTiSaR soft tissue sarcoma, STS soft tissue sarcoma,
WT Wilm’s Tumor
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Besides the extent of dose reduction, the cut-off for
termination of dose reduction is highly variable. Dose
reductions up to 1 year are included in all studied protocols
(Fig. 1); however, contrary to age-based cut-offs (protocol
A: ALL-BFM; protocol C: CWS-2002, CWSSoTiSaR),
body weight cut-offs are highly dependent on the body
composition of the child. Differences were most obvious in
the small and low-weight child (Fig. 1, solid lines), who
reaches the 10 kg cut-off (protocol D: NB 2004/STS 2006)
at approximately 2 years of age, and the 12 kg cut-off
(protocol B: SIOP WT 2001; protocol E: SIOPEN HR-
NBL-1) at approximately 3 years of age. In the child with a
typical body weight and height (Fig. 1, dotted lines) the
10 kg cut-off is reached at an age marginally above 1 year,
and the 12 kg cut-off is reached at an age of approximately
2 years. With regard to the tall and obese child, only a
small difference in the maximal age of dose reduction was
observed (all 1 year, or marginally above 1 year) (Fig. 1,
dashed lines).
Based on this evaluation, clinicians should ask
themselves whether they want to accept differences of
up to one-third when dosing the patient according to
one protocol or another. Another question to consider
would be whether the maturation of a child can be
adequately reflected by such discrete steps in a dosing
algorithm.
Age [years]




























































































Fig. 1 Effect of different dose
adjustment schemes on the
relative proportion of BSA dose
administered to hypothetical
patients on the 5th (solid line),
50th (dotted line) and 95th
(dashed line) percentile of
height and body weight.
a protocol A; b protocol B;
c protocol C; d protocol D;
e protocol E according to
Table 1; and f the dose
adjustment based on the
population pharmacokinetic
model (in case no dose-
adjustment based on body
weight was recommended by
the protocol, only one solid line
is present). BSA body surface
area
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3.2 Impact of Different Dose Recommendations
on the Affected Patient Cohort of the EPOC-
MS-001-DOXO Trial
The EPOC trial was performed in order to systematically
investigate the pharmacokinetics of doxorubicin in chil-
dren. Overall, 101 children (range 0.2–17.7 years;
\3 years, n = 27), treated according to their tumor-
specific protocols, were recruited [1]. The influence of dose
adaptations in different protocols (Table 1) was evaluated
in patients in the EPOC study specifically affected by
protocol differences (age C1 year, body weight \12 kg).
The analysis was carried out using the actual BSA, body
weight and age of the patients.
The EPOC population included a number of children
who were anomalously affected by the body-weight-based
cut-offs: four children were older than 1 year of age, but
below 10 kg (1.38, 1.42, 1.43 and 1.68 years), and six
children were older than 1 year of age and between 10 and
12 kg (1.04, 1.59, 1.94, 2.29, 2.53 and 4.15 years). Thus, 9
of 19 children between 1 and 3 years of age, and one child
above 3 years of age, would receive different doses
depending on the protocol, resulting in pronounced dif-
ferences in the administered percentage of BSA dose
(Table 2). For example, the child aged 2.53 years, weigh-
ing 11.9 kg, would receive 66 % of the reference dose
based on the BSA of protocol B (SIOP WT 2001), 75 % of
the dose based on protocol E (SIOPEN HR-NBL-1), and a
full BSA dose when enrolled in any of the other three
treatment protocols (Table 2).
Although body weight, including outliers, was evenly
distributed in children younger than 5 years of age (20
patients below and 23 patients above the 50th percentile of
body weight), the data of the EPOC trial underline that
typical pediatric cancer populations include a broad
variability of individuals, including outliers. Five of 43
children younger than 5 years of age were below the 5th
percentile of height and body weight (Table 2). In such
specific cases, a multidisciplinary consensus on dosing
options should be considered, informed by the considera-
tions presented in this article.
4 What Should We Aim at When Developing
Pharmacokinetic-Guided Dosing?
Unlike busulfan [19], methotrexate [20] and carboplatin
[21], no target parameter, such as area under the concen-
tration–time curve (AUC), maximal plasma concentration
(Cmax), minimal plasma concentration (Cmin) or time-over-
threshold concentration, has been defined for anthracy-
clines. In contrast, the effect of pharmacokinetic parame-
ters on toxicity has been studied. It is widely accepted that
a higher exposure to the drug, as represented by a higher
cumulative dose, is associated with a higher risk of cardiac
damage [22, 23], but the question of whether a high Cmax is
associated with a greater risk of cardiac injury is
controversial.
Some publications imply that higher Cmax is associated
with significantly higher rates of congestive heart failure
(CHF) when applying the same dose [24]. One investiga-
tion including 3184 children and comparing a 3-weekly
schedule of doxorubicin with a weekly schedule (mean
cumulative dose 240 mg/m2) found a 2.9 and 0.8 % rate of
CHF in the 3-weekly and weekly dose groups, respectively
[25]. However, another large study in children with ALL
did not find a significant difference in cardiac function
when comparing 1 h and 48 h infusions [26]. Since the
most appropriate duration of infusion is unknown, there
must be a balance between the risk of cardiotoxicity and
Table 2 Effect of different
dose recommendations on
patients in the EPOC-MS-001-
Doxo trial
Age, years Body weight, kg % of BSA dose Min. of A–E Max. of A–E
A B C D E
1.04 11.4 100 67 100 79 100 67 100
1.38 7.9 100 67 100 64 64 64 100
1.42 9.8 100 67 100 70 70 67 100
1.43 8.3 100 67 100 66 66 66 100
1.59 11.2 100 67 100 74 100 67 100
1.62 9.0 100 67 100 67 67 67 100
1.94 10.5 100 67 100 72 100 67 100
2.29 10.3 100 67 100 69 100 67 100
2.53 11.9 100 67 100 76 100 67 100
4.15 11.5 100 67 100 75 100 67 100
Letters (A–E) correspond to the protocol dose reductions in Table 1
EPOC European Paediatric Oncology Off-Patent Medicines Consortium, Doxo doxorubicin BSA body
surface area, min. minimum, max. maximum
Towards a Model-Based Dose Recommendation for Doxorubicin 219
patient convenience. Obviously, the dose administered
must also be taken into account when selecting the duration
of infusion.
As dose intensity is presumed to be the most relevant
pharmacokinetic parameter for cytotoxic drugs, it might be
reasonable to focus on the most commonly used measure of
AUC. However, this approach does not directly consider
the impact on other measures such as Cmax or time-over-
threshold concentration, which have been intensively dis-
cussed for other drugs such as etoposide [27]. For a given
infusion duration, these parameters vary proportionately. In
addition, the optimal AUC for each treatment protocol
depends on the other cytostatic drugs administered in
combination with doxorubicin.
Taking the strategy of targeting AUC as an example, a
further relevant question should be whether the aim is to
achieve a uniform AUC across all patients. On the other
hand, it could also be reasonable to target a lower AUC
while maintaining efficacy, or even accepting lower effi-
cacy in the very young as this is likely to be the population
at highest risk for developing long-term toxicities such as
CHF [8, 28]. Alternatively, a potentially higher AUC, and
likely associated higher adverse event rate, could be
accepted if a higher rate of cure resulted, as has been
shown for acute myeloid leukemia [12].
No matter which parameter will be the focus of dosing,
all parameters show wide intraindividual and interindivid-
ual variability. As the developed model shows considerable
intraindividual variability on the central volume of distri-
bution [1], a routine application of therapeutic drug mon-
itoring would be unlikely to aid dose-finding in individual
patients. A calculation rule has to therefore prioritize
probabilities: not to exceed maximum AUCs/concentra-
tions, not to fall short on minimums, and to fit for defined
percentages of patients.
When attempting to develop dose adaptations, we also
need to bear in mind that the number of children younger
than 1 year of age studied to date is low. The EPOC trial is
the largest and most recent trial of doxorubicin in children.
Although, there was a specific focus on children less than
3 years of age, the EOPC trial included only four children
younger than 1 year of age. The reasons for this lack of
data are the rarity of oncologic diseases in this age group
and the difficulty of recruiting such vulnerable subjects into
clinical trials.
5 How Could We Attempt to Develop a Model-
Based Dose Recommendation in Children?
In order to attempt to develop a dose adaptation, the pop-
ulation pharmacokinetic model of the EPOC trial, recently
developed by our working group, was utilized [1]. The
pharmacokinetics could be described by a three-compart-
ment model in which all parameters were linearly scaled to
BSA. In addition, the influence of age was modeled as a
power function on CL.
Individual CL (CLi) was given using the following
equation (Eq. 2):
CLi ¼ CLp  egi  1 þ BSAi  BSAmedianð Þ  1:3ð Þ




where CLp represents the population estimate of CL, gi
represents the deviation of the individual patient from the
population value of CL (L/h), and BSAi (m
2) and Agei
(years) represent the individual age and BSA of each
patient.
Based on this model, CL increases linearly with BSA;
however, the model predicts an additional maturation of
CL with age. CL (L/h/m2) increases rapidly in the very
young, leveling off in older children (approximately
3–4 years). The predicted CL of a full-term newborn
(BSA 0.22 m2) was 12.0 L/h/m2, while the model pre-
dicted a CL of 29.1 L/h/m2 in an 18-year-old (BSA
1.8 m2) [1].
During the development of the dose adaptation, it was
assumed that a similar target drug exposure, calculated as
AUC, should be attained in children of all ages. The AUC
of an 18-year-old child (AUC18 years) was defined as the
target AUC for all children, as maturation can be consid-
ered complete at that age and this approach might allow
bridging to data available in adults.
Using Eq. 2, the nominal CL (L/h) was calculated for
children of different ages and converted into the BSA-ad-
justed CL (L/h/m2). As the AUC is defined by the ratio of
the applied dose and the individual patient’s CL (L/h), the
dose (mg/m2) to be administered to a patient can be cal-
culated using the product of CL (L/h/m2) and AUC. In
order to reach AUC18 years, the dose applied to an 18-year-
old (Dose18 years) is multiplied by the ratio of CLi to









































Therefore, the percentage of the protocol dose to be
applied to children of different ages, given using the ratio
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of CLi and CL18 years, is displayed in Table 3. The CL (L/h/
m2) of a 1-year-old child is predicted to be 67 % of that of
an adult, and the dose (mg/m2) resulting in a comparable
AUC would be 67 % of the full dose (mg/m2) administered
to an 18-year-old (Table 3). CL was associated with an
interindividual variability of approximately 31 % in the
developed model. Thus, using this dosing proposal, AUCs
in patients would be subject to the same degree of
variability. For the impact of such a dose adjustment on
the plasma concentration–time curve in a 1-year-old
administered 20 mg/m2 over 4 h (see Fig. 2). While AUC
is significantly lower, Cmax is also reduced by
approximately 30 % in this example.
The model suggests that due to the close agreement
between CL18 years and CLi (86 vs. 100 %), dose adaptation
would not be necessary over the age of 7 years (Table 2).
Under the described proposal, a median AUC of 0.675 mg/
Lh (range 0.52–2.24) could be achieved in children
younger than 3 years of age, compared with 0.678 mg/Lh
(range 0.41–1.52) in older children, when taking the EPOC
population as a hypothetical example. Figure 1f illustrates
that the dose adaptation based on the pharmacokinetic
model could provide a smooth transition based on age.
When comparing the evaluated dose adaptations with
the proposed dosing regimen, body-weight-based dose
reductions perform slightly better than proportional
reductions based on the BSA dose. The closest agreement





CL predicted by the
model, L/h
CL predicted by the
model, L/h/m2
% of adult CL predicted by the
model, L/h/m2
Proposal: % of BSA dose to be
administered
0.25 0.33 5.62 17.02 59 59
0.5 0.39 7.07 18.12 62 62
0.75 0.42 7.93 18.88 65 65
1 0.45 8.76 19.47 67 67
1.5 0.50 10.19 20.39 70 70
2 0.55 11.61 21.11 73 73
2.5 0.59 12.81 21.71 75 75
3 0.62 13.78 22.23 76 76
3.5 0.65 14.75 22.69 78 78
4 0.68 15.71 23.11 79 79
5 0.75 17.88 23.84 82 82
6 0.79 19.33 24.47 84 84
7 0.88 22.13 25.04 86 100
8 0.96 24.52 25.55 88 100
9 1.07 27.83 26.01 89 100
10 1.14 30.14 26.44 91 100
11 1.20 32.27 26.84 92 100
12 1.30 35.38 27.21 94 100
13 1.41 39.00 27.57 95 100
14 1.51 42.16 27.90 96 100
16 1.72 49.05 28.52 98 100
18 1.80 52.35 29.08 100 100
CL values and percentage of adult CL are predicted based on the population pharmacokinetic model of the EPOC trial

























Fig. 2 Plasma concentration–time curve of a 1-year-old child with
median height and body weight with (blue line) and without (red line)
the application of the developed dose reduction scheme; infusion
duration 4 h, full BSA dose 20 mg/m2. BSA body surface area
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was observed with protocol E (SIOPEN HR-NBL-1;
Fig. 1e), which reduces the dose based on body weight in
children up to 12 kg. However, our approach would pro-
pose dose reduction based on age instead of body weight,
and recommend this be applied in children up to the age of
7 years (Table 3).
Besides all these considerations, the data of the trial and
the associated model show that dosing guidelines should
reflect model variability. Ninety percent of the estimated
CL values of the EPOC trial were within a twofold range;
however, the population included outliers with consider-
ably lower CL values. Considering this, even developing a
more sophisticated dosing rule might not result in the
achievement of a target AUC in all patients, and variability
may be more pronounced in the very young.
Thus, translating dose adaptations based on pharma-
cokinetics into acceptable proposals for tumor-specific
treatment groups fundamentally requires the identification
and validation of target parameters. These parameters
should be suitable as surrogates for clinical endpoints of
interest and must take into account probabilistic aspects.
6 Conclusions
The considerations presented here offer the opportunity to
discuss how to achieve a model-informed dose-reduction
for doxorubicin based on pharmacological data, in contrast
to the commonly used empirical dose adaptations. Visu-
alizing the effects of commonly applied protocols high-
lights the need for a consensus in dose recommendations in
the very young as considerable differences among various
protocols are apparent. It would be highly desirable to
establish one consistent dosing strategy for all cancer
entities, and to prospectively validate this strategy with
regard to efficacy and safety in clinical trials.
The clinical setting of rare diseases, with very small
patient numbers, vulnerable infants, and a drug with
complex pharmacokinetics, does not lend itself easily to
the running of subsequent trials. Therefore, the next trial
should be based on optimal modeling and simulation pro-
cesses [29] as well as a well-established consensus on the
goals (Table 4). If anyone would like to participate in such
a process, they are welcome to contact the authors. Do we
need age-specific dose calculations to adapt to age-depen-
dent pharmacokinetic parameters, to reflect age-dependent
vulnerability of target organs or to hit a smaller therapeutic
gain?
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